What is claimed is:

1. A compound according to formula (I) hereinbelow:



(I)

wherein:

R_1 represents NR_4R_5;

R_2 represents $CONH_2$ or SO_2NH_2;

R_3 represents up to three substituents selected from the group consisting of halogen, C_{1-4}alkyl, NH_2, CF_3, OCF_3, O-alkyl, S-alkyl, CN, CHO, SO_2-alkyl, and NO_2;

R_4 represents H, C_{1-2} alkyl;

R_5 represents $C(=A)NHR_6$, COR_7, or R_6;

A represents O, S, or N;

R_6 represents H, or C_{1-2} alkyl;

R_7 represents C_{1-2} alkyl;

L represents a linker D-E-D such that

D represents a bond or C_{1-4} alkyl;

E represents  ; and

G and I independently represent H, C_{1-2} alkyl; or a pharamceutically acceptable salt thereof, provided that the compound of formula (I) is not 2-[(aminocarbonyl)amino]-5-{[(4-chlorophenyl)methyl]oxyl-3-thiophenecarboxamide.

2. A compound according to claim 1 wherein R_2 is $CONH_2$.

3. A compound according to claim 1 wherein R_5 is $C(=A)NHR_6$.

4. A compound according to claim 1 wherein A is O.

5. A compound according to claim 1 wherein E is

C = C, CONH, or ≡ .

6. A compound according to claim 1 wherein the compound is selected from the group consisting of:

5-[(E)-phenyl)-ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;

5-[(E)-2-(4-Fluoro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acidamide;

5-[(E)-2-(4-Chloro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;

5-Phenethyl-2-ureido-thiophene-3-carboxylic acid amide;

5-Benzyl-2-ureido-thiophene-3-carboxylic acid amide;

5-(1-Phenyl-ethyl)-2-ureido-thiophene-3-carboxylic acid amide;

5-Phenylethynyl-2-ureido-thiophene-3-carboxylic acid amide;

5-(4-Fluorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;

5-(4-Ethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;

5-(4-Methoxyphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;

5-(4-Chlorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide ;

5-(4-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;

5-(3-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide; and

5-Acetylamino-thiophene-2,4-dicarboxylic acid 4-amide 2-[(3-chloro-phenyl)-amide]; or a pharmaceutically acceptable salt thereof.

7. A method of treating a disease characterized by pathological NF-κB activation comprising inhibiting the pathological activation by administering to a patient in need thereof an effective amount of a compound according to claim 1.

8. A method according to claim 7 wherein the disease is an inflammatory or tissue repair disorder.

9. A method according to Claim 8 wherein the disease is selected from the group consisting of inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases, dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage, autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including aquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiestasia.

10. A method according to claim 7 wherein said disease is COPD.

11. A method according to claim 7 wherein said disease is asthma.

12. A method according to claim 7 wherein said disease is rheumatoid arthritis.

13. A method according to claim 7 wherein said disease is dermatosis.

14. A method according to claim 7 wherein the disease is selected from the group consisting of: psoriasis, atopic dermatitis, and UV-induced skin damage.

15. A method according to claim 7 wherein the disease is selected from the group consisting of autoimmune diseases; tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, osteoarthritis, osteoporosis, and Ataxia Telangiestasia.

16. A method according to claim 7 wherein said disease is an autoimmune disease.

17. A method according to claim 9 wherein the autoimmune disease is systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, or alkylosing spondylitis, diabetes

18. A method according to claim 7 wherein the disease is cancer and or cachexia.

19. A method according to claim 7 wherein the cancer is Hodgkins disease.

20. A method according to claim 7 wherein the disease is inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS).

21. A method according to claim 7 wherein the disease is AIDS.

22. A method according to claim 7 wherein the disease is adult respiratory distress syndrome.